Sign in
Taking people in South KoreaNo phase

Retinal photo tool to predict heart risk in new heart failure patients

Tests a retinal photo risk score in adults newly diagnosed with reduced-ejection heart failure.

Key facts

Who runs it
Yonsei University
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Validation of the Prognostic Impact of a Retinal Photograph-based Cardiovascular Disease Risk Stratification System in de Novo HFrEF
Status
Recruiting
People taking part
100 people, planned
Started
10 Dec 2024
Expected to end
10 Dec 2030
Type of study
Observational
Record updated
18 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 20 to 79 with newly diagnosed heart failure and a weak heart pump (ejection fraction of 40% or less). It tests whether a photograph of the back of the eye can predict outcomes.

Age
20 to 79 years
Sex
All sexes can join.
Disease stage
Left ventricular ejection fraction of 40% or less, measured by an ultrasound of the heart (transthoracic echocardiography). The title says newly diagnosed heart failure.

Main reasons for not taking part

  • Severe eye disease that prevents good-quality photos of the back of the eye
  • Extensive retinal disease that makes the retinal blood vessels hard to see
  • Pregnant individuals
  • People who cannot decide for themselves whether to take part
  • People who decline to give informed consent

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients aged between 20 and 79 years with a left ventricular ejection fraction of 40% or less (assessed by transthoracic echocardiography), who have provided written consent for participation, have the capability to consent voluntarily

Who cannot take part

  • Inability to obtain high-quality fundus photographs due to severe ophthalmologic conditions
  • Presence of extensive retinal diseases that significantly impair visualization of the retinal vasculature
  • Decline to provide informed consent for study participation, including:
  • Pregnant individuals
  • Individuals lacking decision-making capacity

Where in South Korea

  • Severance hospitalSeoul, South KoreaContact: Chan Joo LeeTaking people

About the trial

What the trial wants to find out

"Despite significant advances in pharmacologic and device-based therapies, heart failure (HF) remains a major public health burden, with persistently high rates of hospitalization, impaired quality of life, and excess mortality-often exceeding those of leading malignancies. Prognosis in HF is shaped by its underlying etiology: ischemic HF often responds to revascularization strategies, whereas non-ischemic HF, particularly due to idiopathic or genetic cardiomyopathies, demonstrates highly variable outcomes and limited responsiveness to guideline-directed medical therapy (GDMT). Although left ventricular reverse remodeling (LVRR) is associated with favorable outcomes, only 40-50% of non-ischemic HF patients achieve meaningful LVRR with GDMT alone.

Read full original descriptionShow less

In this context of therapeutic uncertainty and prognostic heterogeneity, there is a critical need for novel, non-invasive risk stratification tools. Retinal imaging offers a unique advantage, enabling direct, in vivo visualization of systemic microvascular and neurovascular integrity. Prior work from our group has demonstrated that deep learning algorithms applied to retinal fundus photographs can estimate physiologic and metabolic markers-including CAC scores-and predict future cardiovascular events. The Reti-CVD scoring system, derived from these models, has been externally validated in independent populations.

In the present study, we aim to evaluate the prognostic utility of the Reti-CVD model in a cohort of patients with newly diagnosed HF and reduced ejection fraction. Specifically, we will assess whether retinal-derived risk scores at baseline are associated with adverse clinical outcomes, including cardiovascular events and all-cause mortality, and whether prognostic performance varies according to HF etiology."

The group in the trial

  • De novo Heart Failure cohort

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Validation of the Prognostic Impact of a Retinal Photograph-based Cardiovascular Disease Risk Stratification System in de Novo HFrEF
Plain-language title
Retinal photo tool to predict heart risk in new heart failure patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
18 May 2025